Skip to main content
. Author manuscript; available in PMC: 2008 Oct 2.
Published in final edited form as: Cell Cycle. 2008 May 14;7(14):2225–2233. doi: 10.4161/cc.7.14.6303

Figure 4. MDC1 and BRIT1 were negative regulators of Aurora A and Plk1.

Figure 4

(A) U2OS cells were transfected with luciferase siRNA or MDC1 siRNA (left) or BRIT1 siRNA (right). At 48 h after transfection, cells were harvested and the lysates were subjected to Western blotting using antibodies against (left) MDC1, Plk1 and Aurora A or (right) BRIT1, Plk1 and Aurora A. Actin is for the loading control. (B) U2OS cells were transfected with the siRNA against luciferase, MDC1, or BRIT1. At 48 h after transfection, cells were untreated or treated with cycloheximide for 8 or 12 h. Cells were then harvested, and the lysates were subjected to Western blotting using antibodies against Plk1, Aurora A or actin. (C) U2OS cells were transfected with siRNA against luciferase or MDC1 along with cotransfection of empty expression vector or the vectors expressing wild-type pEGFP-C2-MDC1 or pEGFP-C2-ΔFHA-MDC1 mutant. At 48 h after the transfection, cells were harvested, and the lysates were subjected to Western blotting using antibodies against MDC1, Plk1, Aurora A. Actin is used for the loading control.

HHS Vulnerability Disclosure